Biologically Derived Therapies – Evaluating Their Hazards and Controlling Their Exposures

Evaluating the hazards of biologically derived drug therapies is different from that of small molecules. The data generated for regulatory agencies can be vastly different than that for small molecules making the criteria matrices for categorization difficult to use. In addition, the operations performed in development and manufacturing as well as the risks of exposure while handling can be different. The webinar will highlight similarities and differences between categorization and handling of biologically derived therapies from small molecules.

Who Should Attend:

  • Industrial hygienists
  • Occupational toxicologists
  • Production supervisors
  • Development scientists
  • Facility managers

  • Webinar topics

    Register now

    $195

    May 04, 2021 -- Online
    9:00 AM Eastern time
    May 04, 2021 -- Online
    2:00 PM Eastern time